26 Feb 2010
FDA Press Release - FDA Approves Therapy to Treat Gaucher Disease
New drug will offer a treatment alternative for patients with rare genetic disorder
SILVER SPRING, Md., Feb. 26 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease.
See the FDA's full press release here.
SOURCE U.S. Food and Drug Administration
Did you know...
You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.
Did you know...
We donated over $35,000 in
outdated laboratory
equipment to local
schools?
